Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The company expects the funding to bring it into the clinic and is also in partnering talks with academic institutions and biopharma companies, said co-founder Jonathan Lim, who previously led Ignyta.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.